Interleukin-2: NIH began a Phase II trial in 90 patients, testing combinations of the two anti-TNF agents to counteract side effects of IL-2, which raises CD4 c

The one-year trial will compare IL-2 alone to IL-2 with either agent. Primary end points will be safety and tolerability of the combinations, with secondary end points to be changes in CD4 cell counts...